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Background: The present meta-analysis aimed to examine to what extent combined pharmacotherapy
with psychotherapy results in a different response to treatment compared to psychotherapy or phar-
macotherapy alone in adults with major depression at six months or longer postrandomization.
Methods: A systematic literature search resulted in 23 randomized controlled trials with 2184 partici-
pants. Combined treatment was compared to either psychotherapy or anti-depressant medication alone
in both the acute phase and the maintenance phase. Odds ratios of a positive outcome were calculated
for all comparisons.
Results: In acute phase treatment, combined psychotherapy with antidepressants outperformed anti-
depressants alone at six months or longer postrandomization in patients with major depressive disorder
(OR¼2.93, 95%CI 2.15–3.99, po0.001). Heterogeneity was zero (95%CI 0–57%, p40.05). However,
combined therapy resulted in equal response to treatment compared to psychotherapy alone at six
months or longer postrandomization. As for the maintenance treatment, combined maintenance psy-
chotherapy with antidepressants resulted in better-sustained treatment response compared to anti-
depressants at six months or longer postrandomization (OR¼1.61, 95%CI 1.14–2.27, po0.05). Hetero-
geneity was zero (95%CI 0–68%, p40.05).
Conclusions: Combined therapy results in a superior enduring effect compared to antidepressants alone
in patients with major depression. Psychotherapy is an adequate alternative for combined treatment in
the acute phase as it is as effective as combined treatment in the long-term.
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Depression is a highly prevalent disorder and one of the leading
causes of disability worldwide. According to the World Health Or-
ganization (WHO), depression is currently the fourth largest con-
tributor to the global burden of disease and is expected to become
the second cause of disability by 2020. This is a result of the re-
current nature of depression and its excessive economic costs,
mortality, and morbidity rates (Reddy, 2010). Therefore, it is crucial
for clinical decision making to identify which therapeutic strategies
should be employed to produce the most favorable outcome in the
treatment of depression in both the short and the long term.
There is ample evidence for the short-term effects of psy-
chotherapies and pharmacological treatments for depression in
the acute (aimed at alleviating the symptoms of an active de-
pression) and the maintenance phase (aimed at preventing future
recurrence of the depressive disorder) (Akechi et al., 2008; Belt-
man et al., 2010; Casacalenda et al., 2002; Cuijpers et al., 2011;
Cuijpers and Dekker, 2005; Dennis et al., 2007; Kennedy, 2013;
Pizzi et al., 2011; Williams et al., 2000). Meta-analytic studies have
shown that, at post-treatment, the effects of psychotherapy and
pharmacotherapy in treating mild to moderate depression are
comparable (Cuijpers et al., 2013, 2008b), with a combination of
pharmacotherapy and psychotherapy showing the best treatment
effects when compared to pill placebo, pharmacotherapy and
psychotherapy alone (Cuijpers and Dekker, 2005; Cuijpers et al.,
2009, 2014, 2012; Khan et al., 2012; Pampallona et al., 2004).
However, the long-term effects of the combination of psy-
chotherapy and pharmacotherapy are not well known.
Cuijpers et al. (2009) conducted a meta-analysis to examine the
effects of combined psychotherapy with pharmacotherapy versus
psychotherapy alone. The authors found no differences in the ef-
fects between combined treatment and psychotherapy in the fol-
low up in patients with depression. However, Cuijpers et al. (2009)
also included short time intervals in their definition of long-term
outcomes, e.g., 1 month follow up (Cuijpers et al., 2009). Thus, an
examination focusing specifically on longer follow up periods is
warranted. Barber et al. (2013) conducted a systematic review to
examine the absolute and relative efficacy of dynamic therapy in
treating several mental disorders, such as depression and anxiety.
The authors reported that dynamic therapy in combination with
pharmacotherapy resulted in significantly higher remission rates
compared to pharmacotherapy alone in adults with depression in
the long-term (Barber et al., 2013). However, the number of in-
cluded studies was small (n¼3) and the results cannot be gen-
eralized to other types of psychotherapy. To our knowledge, no
systematic review has examined the effects of combined treat-
ment of all major types of psychotherapy and pharmacotherapy
against pharmacotherapy alone in adults with major depressive
disorder (MDD) in the long term.
Existing treatment guidelines recommend that the provision of
antidepressant treatment should last for at least six months in
order to prevent recurrence (American Psychiatric Association,
2000). Thus, it is essential to further examine the effects of com-
bined therapy in the long term; such knowledge will provide in-
sight into which therapy we should consider as first line treatmentfor major depression. The present meta-analysis aimed to examine
to what extent combined pharmacotherapy with psychotherapy
results in a different response to treatment compared to psy-
chotherapy and pharmacotherapy alone in adults with major de-
pression at six months or longer postrandomization.2. Methods
This study is based on a more extensive report for the devel-
opment of treatment guidelines on the long-term effects of psy-
chotherapy on depression (Karyotaki et al., 2014).
2.1. Search strategy
We conducted a systematic literature search in the biblio-
graphic databases of Medline, PsycInfo, Embase and the Cochrane
library from database inception to September 1, 2014. Detailed
search strategies for PubMed are given in Appendix A. This search
strategy was combined with a filter for systematic reviews pro-
vided by PubMed (http://www.nlm.nih.gov/bsd/pubmed_subsets/
sysreviews_strategy.html) and a filter for RCTs as recommended in
the Cochrane Handbook (Higgins and Green, 2011). Search stra-
tegies for other databases were built accordingly.
In addition to the systematic literature search, we checked the
references of the selected studies as well as other systematic re-
views and meta-analyses in order to identify additional relevant
studies. Moreover, we checked an existing database of randomized
trials on psychotherapy for depression that has been used by several
meta-analyses and is updated yearly (Cuijpers et al., 2008c).
After removal of duplicate publications, two researchers (EK
and YS or DB supervised by PC) independently examined titles and
abstracts to remove records that were obviously not relevant to
the research question according to the guidelines of the Cochrane
Handbook (Higgins and Green, 2011). Studies that possibly met
inclusion criteria were retrieved full-text and were examined by
the same two researchers independently. Any disagreement re-
garding the inclusion was solved through discussion, and if nee-
ded, the opinion of a third researcher (PC) was sought.
2.2. Study selection
We included all main psychotherapy interventions that have
been identified in an expert taxonomy of psychotherapy for adult
(Z18 years of age) depression (Cuijpers et al., 2008a). Here, psy-
chotherapy was classified into seven different types: behavioral
activation, cognitive-behavioral therapy, interpersonal therapy,
problem solving therapy, psychodynamic therapy, social skills
training, and supportive counseling. Operational definitions of
each type of psychotherapy are given elsewhere (Cuijpers et al.,
2008a, 2008b). We considered for inclusion acute phase treat-
ments as well as maintenance treatments (definitions are given in
Table 1) and distinguished these throughout the analyses. The
selected interventions were main psychotherapy interventions
combined with antidepressive agents compared to main psy-
chotherapy intervention or antidepressants alone.
Table 1
Definitions.
Psychotherapy Psychotherapy was defined as an intervention in which verbal communication between a therapist and a patient is the core element, or in
which a psychological treatment is contained in book format (bibliotherapy) or electronic format (internet-based treatment) that the patient
works through more or less independently, but with some kind of personal support from a therapist (guided by telephone, e-mail, or
otherwise) (19)
Acute phase treatment Therapy during the occurrence of depressive symptoms that is targeted at alleviating the symptoms of an active major depressive episode
Maintenance treatment Therapy in which patients receive maintenance treatment sessions at low frequency rates, for example once monthly, and is aimed at pre-
venting future recurrences of major depressive episode
E. Karyotaki et al. / Journal of Affective Disorders 194 (2016) 144–152146The primary outcomes of the present meta-analysis were
treatment response and sustained response. Treatment response
was defined as every positive outcome achieved, such as whether
a patient met criteria for remission or was free from relapse or
recurrence. Moreover, sustained response was defined as a treat-
ment response that was continued during and after maintenance
treatment. Other outcomes were condition-related outcomes
(depression rating scales).
Only outcomes at six months or longer after randomization
were considered for inclusion. This cut off was chosen because
remission is defined as the absence of a depressive disorder three
months after the end of therapy, and because anti-depressant
medication needs to be provided for at least six months (American
Psychiatric Association, 2000). Additionally, a later time point for
the cut off did not seem feasible as few studies have a longer
follow up period. Outcomes were extracted for different time
periods (six months and one year or longer).
2.3. Quality assessment
Two reviewers assessed study quality independently (EK and
YS) based on the criteria of the Cochrane Risk of Bias tool (Higgins
and Green, 2011). Disagreement was resolved through discussion
and, if needed, the opinion of a third researcher (PC) was sought.
2.3.1. Data extraction
The following data were extracted from the included RCTs:
patient characteristics, type of psychotherapy, treatment format,
number of treatment sessions, type of pharmacotherapy, type of
control and data on the follow up period. In some studies, out-
come data were only reported for patients who responded to
treatment in the acute treatment phase, while others report out-
comes for the full, intention-to-treat sample. When available, in-
tention-to-treat data were selected. One reviewer (EK) extracted
data; a second reviewer (PC) checked the extracted data.
2.4. Description of the analysis
The primary focus was on dichotomous outcomes. We calculated
for each comparison the odds ratio (OR) of a positive outcome, based
on dichotomous results, such as remission and response, or the pro-
portion of patients that no longer met criteria for a depressive disorder
according to a diagnostic interview. The OR shows the odds that an
event (e.g. treatment response) will occur in the treatment group (e.g.
combined therapy) compared to the odds of the same event occurring
in the control group (e.g. psychotherapy or antidepressants alone). An
OR41 increases the odds that an event will occur in the treatment
group. Reversely, an ORo1 decreases the odds that an event will occur
in the treatment group (Deeks et al., 2008). Generally, an OR of 1.5 is
considered a small effect size, while an OR of 2.5 and OR of 4 represent
a medium and a high effect size respectively (Rosenthal, 1996).
Where more than one dichotomous outcome was reported, we
calculated the mean of the effect sizes according to Borenstein
et al. (2009) procedures. Thus, each comparison resulted in only
one effect. If no dichotomous outcomes were reported, the stan-
dardized mean difference (SMD) was calculated as the differencein mean scores divided by the pooled standard deviation. The SMD
was converted into the OR according to the procedures given
by Borenstein et al. (2009). For dichotomous outcomes all rando-
mized patients were taken as the denominator, and reported
outcomes in completers were taken as the numerator. To calculate
pooled relative risks, we used the computer program Compre-
hensive Meta-Analysis (version 2.2.021). Because we expected
considerable heterogeneity among the studies, we used the ran-
dom effects model in order to pool the studies.
2.5. Heterogeneity
As a test of homogeneity of effect sizes, the I2-statistic was
calculated which is an indicator of heterogeneity in percentages. A
value of 0% indicates no observed heterogeneity, and larger values
indicate increasing heterogeneity, with 25% as low, 50% as mod-
erate, and 75% as high heterogeneity (Higgins et al., 2003). 95%
confidence intervals (CI) were calculated around I2 (Ioannidis et al.,
2007) using the non-central chi-squared-based approach within
the heterogi module for Stata (Orsini et al., 2005). The Q-statistic
was calculated, and reported when significant.
2.6. Additional analyses
Publication bias was tested by inspecting the funnel plot on
primary outcome measures and by Duval and Tweedie (2000) trim
and fill procedure (as implemented in Comprehensive Meta-ana-
lysis, version 2.2.021). Duval and Tweedie's test estimates the
number of missing studies that might exist in a meta-analysis due
to publication bias. Trim and fill corrects for the resulting asym-
metry in the funnel plot by adjusting the effect size for missing
studies (Duval and Tweedie, 2000). Egger's test of the intercept
was conducted in order to quantify the bias captured by the funnel
plot and test whether it was significant (Egger et al., 1997).
Researcher allegiance for psychotherapy was examined for all
the included RCTs. We evaluated a study as at high risk of re-
searcher allegiance when any of the authors was also involved in
the development of the treatment manual of the psychotherapy
involved. The involvement of a researcher in developing the
treatment under investigation is regarded as a valid indicator of
researcher allegiance, while the validity of other indicators in
reprint measures has been questioned (Munder et al., 2013)
Moderator and subgroup analyses were planned when suffi-
cient studies (at least 3 studies per sub-group) were available.3. Results
After removal of duplicates, we examined 11145 references on
titles and abstracts. This process resulted in 2897 articles being re-
trieved for possible inclusion in the present meta-analysis. In the 23
RCTs that met inclusion criteria, a total of 2184 individuals suffering
from MDD participated in the relevant comparisons combined
therapy, psychological and pharmacological interventions. We iden-
tified 15 RCTs on acute phase treatment and 8 RCTs on maintenance
treatment. Fig. 1 presents the studies selection process.
Fig. 1. PRISMA flow chart of the studies inclusion process.
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through clinical samples, such as general practitioners, outpatient
psychiatric clinics and mental health institutes. One RCT recruited
patients through both clinical and community referrals, one
through community samples, and one did not report the manner
of recruitment. Twenty-one of the 23 trials recruited outpatients,
while two studies included inpatients. The examined RCTs were
conducted across six different countries: Germany (n¼1), Italy
(n¼2), China (n¼1), the Netherlands (n¼2), the United Kingdom
(n¼5) and the United States (n¼12).
Regarding trials on acute phase treatment, the duration of
follow up ranged from six to 48 months after randomization. As
for the maintenance studies, patients entered into either main-
tenance psychotherapy combined with antidepressants or into
maintenance antidepressant medication groups and were fol-
lowed from six to 24 months.
The types of psychotherapy examined across the included trials
were: CBT, interpersonal psychotherapy, problem solving therapy,
psychodynamic supportive therapy, and social skills training.
Acute phase treatment had a duration ranging from six to 29
sessions, while the maintenance psychotherapeutic interventions
consisted of six to 20 sessions that were conducted either weekly/
biweekly or monthly. The antidepressant agents used were the
following: amitriptyline hydrochloride, fluoxetine, fluvoxamine,
imipramine hydrochloride, nortriptyline, or sertraline. Study
characteristics are given in Table 2.
3.1. Differences between combined psychotherapy and anti-
depressants vs. psychotherapy alone or antidepressants alone, acute
phase treatment
Acute phase combined therapy did not differ significantly in
patients' response to treatment, compared to acute phasepsychotherapy at six months (OR¼1.42, 95%CI 0.97–2.07, p40.05)
and one year or longer postrandomization (OR¼1.33, 95%CI 0.88–
2.14, p40.05). Heterogeneity between studies was zero (95%CI 0–
71%, p40.05). There were no indications for publication bias
(Table 3). However, combined psychotherapy with antidepressants
(acute phase) resulted in a better treatment response compared to
acute phase antidepressants after six months or longer post-ran-
domization (OR¼2.93, 95%CI 2.15–3.99, po0.001). Heterogeneity
between studies was zero (95%CI 0–57%, p40.05). There was
some indication of publication bias. Duval and Tweedie's Trim and
Fill procedure indicated that two studies were missing. The im-
puted estimate was 2.71 (95%CI 1.95–3.74). Nevertheless, Egger's
Test was not significant (p40.05). Similar results were observed
for the same comparisons after one year or longer post-
randomization. Combined therapy outperformed antidepressants
in treatment response of outpatients with MDD (OR¼2.23, 95%CI
1.43–3.41). Heterogeneity was zero (95%CI 0–68%, p40.05). Duval
and Tweedie's Trim and Fill procedure indicated a possibility for
publication bias and produced an imputed estimate of 1.97 (95%CI
1.29–3.01), however, Egger's test was not significant (Table 4). The
main outcomes are summarized in Fig. 2.
3.1.1. Sensitivity and subgroup analyses
Two studies on inpatients were excluded in a sensitivity ana-
lysis. Acute phase combined psychotherapy with antidepressants
resulted in better response to treatment compared to acute phase
antidepressants at six months or longer postrandomization in
outpatients with MDD (OR¼2.98, 95%CI 2.07–4.29, po0.001).
Heterogeneity was low (I2¼8%, 95%CI 0–63%, p40.05). There was
some indication of publication bias. Using Trim and Fill the im-
puted value estimate was 2.80 (95%CI 1.89–4.14) while Egger's test
was not significant. A similar pattern of results was observed at
one year or longer postrandomization (Table 3). Sub-group
Table 2
Studies characteristics.
Studies Recruitment Design Any AXIS-II Diag-
nosis (%/ Total N)





Beck et al., 1985 CS RCT 9% CBT & TCA 15 CBT 18 6, 12 BDI, HRSD Acute 1 5 US
Bellino et al., 2006 CS RCT 100% IPT & SSRI 20 SSRI 19 6 Remission (HRSD scores
reductionZ40%)
Acute 0 3 IT
Blackburn et al., 1986 CS RCT/nat.FU NR CBT & TCA 16 TCA 10 6, 12, 18, 24 Response (HRSDo8; BDIo9) Acute 0 5 UK
CBT 15
De Jonghe et al., 2001 CS RCT NR PDST &
SSRI
83 SSRI 84 6 Remission (HRSDo8) Acute 1 4 NL
De Jonghe et al., 2004 CS RCT NR PDST &
TCA/SSRI
101 PDST 107 6 Remission (HRSDr7), Acute 0 3 NL
Frank et al., 1990 CS RCT NR IPT & TCA 25 TCA 28 12, 24, 36 Recurrence (HRSDZ15); survivors
(HRSDo15; Raskino7)
Maintenance 0 4 US
Hersen et al., 1984 Com. S RCT NR SS & TCA 21 TCA 14 6 Depressive symptoms (BDI; HRSD;
REDS)
Maintenance 1 4 US
Hollon et al., 1992;
Evans, 1992
CS RCT NR CBT & TCA 13 TCA 10 24 Relapse (BDIZ16) Acute 0 4 US
CBT 10
Hollon et al., 2014 CS RCT 49.8% CBT &
ADM (NS)
187 ADM (NS) 170 12 Recovery (426 consecutive weeks
without relapse)
Maintenance 0 1 US
Macaskill and Ma-
caskill, 1996
CS RCT 65% RET & TCA 10 TCA 10 6 HRSD; BDI Acute 0 4 UK
Maina et al., 2009 CS RCT NR BDT &
SSRI
65 SSRI 83 48 Remission (HRSDr7) Acute 0 4 IT
Maina et al., 2010 Com. & CS RCT NR BDT &
SSRI
25 SSRI 29 12 Remission (HRSDr7), Acute 0 3 IT
Miller et al., 1989 Inpatients RCT/nat.FU NR CBT & TCA 28 TCA 17 6, 12 Remission (HRDSr7; BDIr9), Acute 0 3 US
Mynors-Wallis et al.,
2000
CS RCT NR PST & SSRI 35 SSRI 36 13 Recovery (HRSD-17r7) Acute 1 1 UK
PST (GP) 39
PST (nurse) 41
Paykel et al., 1999 CS RCT NR CBT & TCA 80 TCA 78 17 Relapse (DSM-III-R) Maintenance 0 3 UK
Perlis et al., 2002 NR RCT NR CBT &SSRI 66 SSRI 66 6 Relapse (HRSDZ15) Maintenance 0 4 US
Reynolds et al., 1999 NR RCT NR IPT & TCA 16 TCA 25 12 Remission (DSM-IV) Maintenance 0 4 US
Reynolds et al., 2006 CS RCT NR IPT & SSRI 22 SSRI 24 12 Recurrence (DSM-IV) Maintenance 1 3 US
Schramm et al., 2007 Inpatients RCT/nat.FU 21% IPT & TCA 65 TCA 65 12 Response (HRSD scores reduction
Z50%); Recovery (HRSDr7)
Acute 0 3 DE
Simons et al., 1986 CS RCT/nat.FU NR CBT & TCA 18 TCA 16 12 Response (BDIo10) Acute 0 4 US
CBT 19
Sirey et al., 2005 CS RCT NR CBT &
ADM (NS)
21 ADM (NS) 24 6 Response (HRSDr10 Acute 1 4 US
Wilkinson et al., 2009 CS RCT NR CBT & SSRI 22 SSRI or TCA 23 6, 12 Recurrence (MADRSZ10; BDIZ12) Maintenance 1 1 UK
Zu et al., 2014 CS RCT NR CBT SSRI 60 SSRI 60 6 Remission QIDSo5 Acute 0 4 CH
CBT 30
ADM: Antidepressant Medication; BDI: Beck Depression Inventory; BDT: Brief Dynamic Therapy; CBT: Cognitive Behavioral Therapy; CH: China; CIDI: Composite International Clinical Interview; Com. S: Community Sample CS:
Clinical Sample; GP: General Practitioner; DE: Germany; DSM: Diagnostic and Statistical Manual of Mental Disorders; FU: Follow Up postrandomization; GP: General Practitioner; HRSD: Hamilton Rating Scale for Depression; IPT:
Interpersonal Psychotherapy; IT: Italy; M: month(s); MADRS: Montgomery Asberg Depression Rating Scale; N: number; NL: Netherlands; NR: Not Reported; NS: Not Specified; PDST: Psychodynamic Supportive Therapy; PST:
Problem Solving Therapy; PT: Psychotherapy; QIDS:Quick Inventory of Depressive Symptomatology-Self- Report; RA: Research Allegiance; RCT: Randomized Controlled Trial; RCT/nat. FU: Randomized Controlled Trial/Naturalistic
Follow Up; SSRI: Selective Serotonin Reuptake Inhibitor; TCA: Tricyclic antidepressant; UK: United Kingdom; US: United States; W: week(s).
a One (1) is given when the study was evaluated as at high risk of researcher allegiance and zero (0) when the study was evaluated as at low risk of researcher allegiance.
b Sum of ‘unclear or high risk of bias’ of the individual quality criteria. The sum is derived after assigning a zero (low risk of bias) or one (unclear or high risk of bias) to each one of the following quality criteria: allocation

















Effect sizes for combined psychotherapy and antidepressants vs. psychotherapy in
adults with MDD, acute phase.
Outcomes N OR 95%CIa I2 95%CI pb
Response at 6 months or longer
postrandomization
8 1.42 0.97–2.07 0 0–68
Subgroups
Type of psychotherapy
CBT vs. 5 1.51 0.79–2.86 0 0–79 0.50
Other 3 1.37 0.85–2.19 0 0–90
Researcher allegiance
No 5 1.53 0.97–2.40 0 0–79 0.60
Yes 3 1.19 0.60–2.40 0 0–90
Response at 1 year or longer
postrandomization
7 1.33 0.88–2.14 0 0–71
Subgroups
Type of psychotherapy
CBT vs. 4 1.48 0.59–3.71 0 0–85 0.80
Other 3 1.24 0.68–2.22 0 0–90
Researcher allegiance
No 4 1.36 0.82–2.25 0 0–85 0.90
Yes 3 1.28 0.64–2.58 0 0–90
Subgroup analyses were conducted only in the cases where at least three com-
parisons were available per group. N: Number of comparisons.
a 95%CI: 95% Confidence Intervals; OR: Odds Ratio; p: p-value.
b p-value between groups.
Table 4
Effect sizes for combined psychotherapy with antidepressants vs. antidepressants
in adults with MDD, acute phase.
Outcomes N OR 95%CIa I2 95%CI pb
Response at 6 months or longer
postrandomization
13 2.93* 2.15–3.99 0 0–57
Subgroups
Type of psychotherapy
CBT vs. 6 3.02* 1.74–5.25 0 0–75 0.88
Other 7 2.87* 1.77–4.64 32 0–71
Risk of bias
Risk of bias r3vs. 4 1.66 0.98–2.81 0 0–85 0.17
Risk of bias 43 5 2.26* 1.35–3.78 13 0–82
Types of antidepressants
SSRI 6 2.64* 1.70–4.11 19 0–64 0.51
TCA 6 3.37* 1.90–5.99 0 0–75
Response at 1 year or longer
postrandomization
8 2.23* 1.43–3.41 0 0–68
Subgroups
Type of psychotherapy
CBT vs. 4 3.37* 1.38–8.21 0 0–85 0.29
Other 4 1.94* 1.16–3.23 0 0–85
Risk of bias
Risk of bias r3 vs. 4 1.94* 1.16–3.23 0 0–85 0.29
Risk of bias 43 4 3.37* 1.38–8.21 0 0–85
Types of antidepressants
SSRI 3 1.64 0.84–3.18 0 0–90 0.22
TCA 5 2.84 1.57–5.16 0 0–79
Sensitivity analysis
Response at 6 months or longer
postrandomization (inpatients
excluded)
11 2.98* 2.07–4.29 8 0–63
Response at 1 year or longer
postrandomization (inpatients
excluded)
6 1.99* 1.14–3.47 0 0–75
Subgroup analyses were conducted only in the cases where at least three com-
parisons were available per group. N: Number of comparisons.
* po0.05.
a 95%CI: 95% Confidence Intervals; OR: Odds Ratio; p: p-value.
b p-value between groups.
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therapy; researcher allegiance vs. no researcher allegiance for
psychotherapy) did not result in statistically significant differences
(Table 4).3.2. Differences between combined psychotherapy with anti-
depressants vs. psychotherapy alone or antidepressants alone in
adults who have had MDD, maintenance treatment
Only one study (Frank et al. 1990) examined the comparison
between combined maintenance psychotherapy with anti-
depressants and maintenance psychotherapy at six months or
longer post-randomization. Thus, we could not examine this
comparison.
Table 5 shows the results of the comparison between main-
tenance combined psychotherapy and antidepressants at six
months or longer postrandomization. Combined maintenance
psychotherapy with antidepressants resulted in a better treat-
ment-sustained response compared to antidepressants at six
months or longer postrandomization (OR¼1.61, 95%CI 1.14–2.27,
po0.05). Heterogeneity was zero (95%CI 0–68%, po0.05). There
was no indication of publication bias. Six studies compared the
outcomes of combined maintenance psychotherapy with anti-
depressants versus antidepressants at one year or longer post-
randomization. Combined maintenance psychotherapy with anti-
depressants resulted in a better-sustained response to treatment
in comparison with antidepressants (OR¼1.73, 95%CI 1.20–2.49,
po0.05) after one year or longer postrandomization. Hetero-
geneity between the studies was zero (95%CI 0–75%, p40.05).
There was no indication of publication bias. Finally, subgroup
analyses (studies with high vs. studies with low risk of bias, CBT vs.
other types of therapy, SSRI vs. TCA antidepressants, and re-
searcher allegiance vs. no researcher allegiance for psychotherapy)
did not result in statistically significant differences.
The main outcomes of our analyses are summarized in Fig. 2.
The forest plots of the main outcomes can be found in Appendix B.4. Discussion
The aim of the present meta-analysis was to examine to what
extent combined pharmacotherapy with psychotherapy results in
a different long-term response to treatment compared to psy-
chotherapy and pharmacotherapy alone in adults with major de-
pression. Results indicated that combined psychotherapy with
antidepressants resulted in an equal acute phase treatment re-
sponse compared to psychotherapy at six months or longer post-
randomization, in adult patients with MDD. Further, combined
psychotherapy with antidepressants resulted in a better acute
phase treatment response compared to antidepressants alone, at
six months or longer postrandomization. As for the maintenance
studies, there was evidence that maintenance-combined psy-
chotherapy with antidepressants resulted in a better-sustained
response compared to maintenance antidepressants alone, at six
months or longer postrandomization.
The results of the comparison between combined therapies
versus antidepressants alone (acute phase treatment) may have
been somewhat overestimated due to publication bias. This in-
dication of publication bias is in accordance with previous meta-
analyses on the same comparison (Cuijpers et al., 2014). However,
the point estimate remained high and significant after the ad-
justment for publication bias.
The results of the present meta-analysis are in line with pre-
vious research, which compared the effects of combined therapy
against antidepressants in patients with depression and anxiety
disorders in the short term (Cuijpers and Dekker, 2005; Cuijpers
et al., 2009, 2014, 2012; Khan et al., 2012; Pampallona et al., 2004).
A recent meta-analysis by Cuijpers et al. (2014) showed that
adding psychotherapy to antidepressants results in overall super-
ior short-term effects compared to antidepressants alone in pa-
tients with MDD, panic disorder and obsessive compulsive
Odds ratio and 95% Cl
Odds   Lower   Upper
ratio   limit   limit
Fig. 2. Main outcomes of combined psychotherapy and antidepressant medications (PT&ADM) in Odds ratio (OR) and 95% Confidence intervals (95%CI).
Table 5
Effect sizes maintenance psychotherapy with antidepressants vs. antidepressants in
adults with MDD.
Outcomes N OR 95%CIa I2 95%CI pb
Sustained response at 6 months or
longer postrandomization
8 1.61* 1.14–2.27 0 0–68
Subgroups
Type of psychotherapy
CBT vs. 4 1.79* 1.19–2.70 0 0–85 0.32
Other 4 1.23 0.64–2.33 0 0–85
Risk of bias
Risk of bias r3 5 1.75* 1.20–2.56 0 0–79 0.28
Risk of bias 43 3 1.07 0.47–2.45 0 0–90
Researcher allegiance
No 5 1.80* 1.21–2.65 0 0–79 0.26
Yes 3 1.12 0.55–2.30 0 0–90
Types of antidepressants
SSRI 3 1.26 0.60–2.64 0 0–90 0.43
TCA 4 1.81* 1.08–3.03 0 0–85
Sustained response at 1 year or longer
postrandomization
6 1.73* 1.20–2.49 0 0–75
Subgroup analyses were conducted only in the cases where at least three com-
parisons were available per group. N: Number of comparisons.
* po0.05.
a 95%CI: 95% Confidence Intervals; OR: Odds Ratio; p: p-value.
b p-value between groups.
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tained during 2 years follow-up (Cuijpers et al., 2014). The present
findings are also in line with the results of Barber et al. (2013) on
dynamic therapy. The authors found that in the long-term dy-
namic therapy combined with antidepressants results in higher
remission rates compared to antidepressants alone in adults with
depression (Barber et al., 2013). Moreover, the finding that acute
phase combined therapy results in no differences in treatment
response compared to acute psychotherapy in longer than
6 months post-randomization is in accordance with Cuijpers et al.
(2009) meta-analysis. Cuijpers et al. (2009) showed that there are
no differences between the effects of combined therapy and psy-
chotherapy at longer than 1 month follow up in patients with
depression (Cuijpers et al., 2009). To the best of our knowledge
there is no systematic review examining the effects of main-
tenance combined therapy.
The present study has several strengths. The included studies
targeted outpatients with MDD and thus, the results of the present
review refer to a highly homogeneous population. Additionally,
our results are based on a direct comparison between acute/
maintenance phase combined treatment and acute phase anti-
depressants/psychotherapy or maintenance antidepressants.
However, the present results should be interpreted with cau-
tion due to several limitations. Most of the included trials used CBT
as a psychotherapeutic intervention, therefore, differences be-
tween different types of psychotherapy could not be examined andthe generalizability of the present findings to all types of psy-
chotherapy is restricted. Similarly, a distinction between depres-
sion severities was not possible because there were no specific
studies with a distinction between mild, moderate and severe
MDD. The outcome was specified to treatment response since the
included studies did not provide enough information on outcomes
assessed by clinical interview. Furthermore, we identified only one
trial on the comparison between maintenance combined therapy
and psychotherapy alone (Frank et al., 1990). Thus, we could not
analyze this comparison and we limited our analysis to the com-
parison between maintenance-combined therapy against main-
tenance antidepressants. Finally, a limitation that should be ac-
knowledged is that the sample at randomization is typically not
the same as the one at long-term follow-up, in spite of using ad-
vanced statistics to model missing data.
With respect to researcher allegiance, a bias of concern in
psychotherapy research (Munder et al., 2013), we did not find
evidence that studies at a high risk of researcher allegiance for
psychotherapy favored psychotherapy more than did studies at a
low risk of researcher bias. However, the number of studies in each
subgroup was small, and we did not examine more subtle forms of
researcher allegiance for psychotherapy such as whether authors
advocated the psychotherapy or the mix of research teams (in-
cluding methodologists and/or psychiatrists). As for our own re-
searcher allegiance, we have carried out in the past a series of
meta-analyses of several different types of psychotherapy and
pharmacotherapy and we do not prefer one treatment to another.
Additionally, we believe that out team is well balanced as it con-
sists of researchers in clinical psychology as well as experts in
evidence-based medicine.
The results of this meta-analysis raise several clinical possibi-
lities. Currently, antidepressants are widely used as first option in
treating major depression in primary and secondary mental health
care (Geddes et al., 2003). Given the high risk of relapse (Keller,
1994), alternative treatment options should also be proposed. The
present findings highlight that the combination of psychotherapy
with antidepressants provides clinical gains in terms of long-term
sustainability of the treatment response. Thus, in light of the en-
during effects, combined therapy may be preferred over mono-
therapy with antidepressants in treatment of major depression.
However, while combined therapy enhanced response rates
relative to antidepressant alone, the present results failed to de-
monstrate a superiority of combined treatment compared to
psychotherapy alone, after acute phase treatment. This might be
due to the limited number of trials on the comparison between
combined therapy and psychotherapy alone and it remains to be
confirmed by future studies. However, it could also indicate that
psychotherapy is in fact a viable alternative for combined treat-
ment, which is important to note for several reasons. Psy-
chotherapy in contrast to medication is not related to side effects
(National Collaborating Centre for Mental Health, 2010) and
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can employ and use to sustain their improvement after the
treatment phase is over. Furthermore, in evidence based practice
the decision-making is based on both treatment effectiveness and
patient preferences. Considering that combined therapy and psy-
chotherapy alone result in equivalent outcomes over the long-
term, patients' preferences is an important factor when choosing
treatment modality. Previous research has shown that some pa-
tients prefer psychotherapy to taking medication (van Schaik et al.,
2004); thus, access to both psychotherapy and pharmacotherapy
in primary and secondary mental health care may increase the
chance of patients following their preferred treatment (Winter and
Barber, 2013).
Further research is warranted to address outcomes such as
quality of life or adverse events, and to examine more types of
psychotherapy. To conclude, the present results suggest that
combined treatment is the best available option both as acute and
as maintenance therapy for treating major depression in the long
term. In addition, if a patient does not prefer the combined
treatment, acute phase psychotherapy could also be a treatment
option as it is as effective as acute phase combined treatment in
the long term.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.jad.2016.01.036.References
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